Depo-Provera MDL Reaches Critical Turning Point as Pre-emption Ruling Looms
The Depo-Provera multidistrict litigation, consolidated as MDL No. 3140 in the Northern District of Florida, is entering a pivotal phase for mass tort law firms managing or evaluating claims tied to alleged meningioma brain tumors. The MDL is overseen by Judge M. Casey Rodgers and centers on allegations that Depo-Provera and related injectable contraceptives can cause users to develop one or more meningiomas, while defendants maintain the products are safe and effective. (flnd.uscourts.gov)
At the center of the litigation is Pfizer’s federal pre-emption defense. Pfizer has argued that the FDA previously rejected proposed label changes related to meningioma risks, meaning state-law failure-to-warn claims should be dismissed. Plaintiffs, however, argue that Pfizer had sufficient risk information and failed to adequately warn patients and healthcare providers earlier. The issue became even more significant after the FDA approved a December 2025 label update adding meningioma risk information to Depo-Provera’s U.S. prescribing information. (FDA Access Data)
For plaintiffs’ firms, the forthcoming pre-emption decision could shape the trajectory of the litigation. A ruling in favor of plaintiffs may allow the claims to proceed into broader discovery, expert development, bellwether preparation, and potential settlement discussions. A ruling for Pfizer, however, could significantly narrow or dismiss many pending claims.
The litigation is also moving toward key scientific and trial milestones. The first bellwether trial is currently scheduled for December 7, 2026, and the court is expected to address expert and causation issues as the cases move deeper into the substantive phase. Public case trackers report thousands of pending claims, with continued growth expected as more potential claimants are evaluated. (Neumann Law Group)
For mass tort law firms, this is the stage where operational discipline becomes critical. Depo-Provera claims may require detailed intake, proof of use, medical history, tumor diagnosis documentation, treatment records, prescribing history, and causation-related evidence. As the MDL advances, firms will need defensible systems to identify viable claims, organize records, monitor deadlines, and prepare inventories for court-driven requirements.
As Depo-Provera litigation moves toward critical rulings and bellwether preparation, Verus helps mass tort firms manage claimant intake, medical record coordination, data validation, and case inventory reporting with accuracy and efficiency. Contact Verus to strengthen your litigation infrastructure and prepare your inventory for the next phase of the MDL.
Emerging Litigation Trends: Key Court Decisions Shaping the Mass Tort Landscape
Depo-Provera MDL Triples in Size
More than 1,300 cases have now been filed in the Depo-Provera MDL in the Northern District of Florida—tripling since its formation in 2024. Plaintiffs allege long-term use caused meningioma brain and spinal tumors. Preemption arguments against Pfizer recently concluded; if plaintiffs prevail, the case will move to the general causation phase.
Georgia Supreme Court Strengthens Plaintiffs’ Rights in Hair Relaxer Litigation
In a pivotal ruling, the Georgia Supreme Court sided with plaintiffs, allowing claims to proceed despite the state’s 10-year statute of repose. The court held that repeated purchases of dangerous products, like chemical hair relaxers, reset the repose period. The decision preserves access to justice for consumers harmed by products used over many years.
GLP-1 Litigation Expands to Include Vision Loss Claims
A new JAMA study links GLP-1 drugs—Ozempic and Mounjaro—to permanent vision loss (NAION). Plaintiffs have filed cases in state courts and petitioned for a New Jersey multi-county litigation. While still early, these developments could broaden the scope of the GLP-1 MDL.
Tylenol Litigation Gains Momentum
Following new federal findings linking prenatal acetaminophen use to autism and ADHD, Tylenol litigation continues before the Second Circuit. Plaintiffs’ counsel cites a 2–3x increased risk of neurodevelopmental disorders, while manufacturer Kenvue disputes any causal link, urging the FDA to reject new warning label petitions.
The Missouri Supreme Court declined Bayer’s appeal, finalizing a $600M judgment for plaintiffs with non-Hodgkin’s lymphoma. With over 61,000 cases pending and $11B already paid, Bayer faces growing pressure for transparency and safer alternatives.
Paraquat MDL Highlights Settlement Tensions
In Illinois, over 6,400 Paraquat lawsuits remain stayed as settlement talks progress. A recent court order underscored tensions between judicial control and attorney advocacy, spotlighting transparency and fairness challenges in large MDL settlements.
Purdue Pharma Bankruptcy Nears Resolution
Purdue Pharma’s revised bankruptcy plan has won 99% creditor approval, potentially unlocking over $7B in opioid crisis settlements, including $850M for individual claimants. A confirmation hearing is set for later this month.
As multidistrict and class action litigations evolve, Verus helps law firms stay ahead through data-driven case management, analytics, and settlement administration.
Contact Verus to streamline your litigation operations and ensure your clients get the support—and justice—they deserve.
